New pill could help vapers kick the habit for good
NCT ID NCT07392125
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether cytisinicline, a plant-based tablet, can help adults quit nicotine vaping. 800 daily e-cigarette users will receive either the drug or a placebo for 12 weeks, plus behavioral support. The goal is to see if more people can stop vaping completely during the final month of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytisinicline (also called cytisine) - a plant-based tablet to reduce nicotine cravings
What this could lead to
If successful, this could provide a new, non-nicotine medication to help people quit vaping, potentially reducing nicotine addiction.
What could go wrong
This is an early Phase 3 trial, so results are not yet known. The drug may not work better than placebo, and side effects are possible. Success depends on long-term abstinence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VAPING CESSATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••